ICON Public (NASDAQ:ICLR) Price Target Raised to $363.00

ICON Public (NASDAQ:ICLR) had its price target boosted by research analysts at Robert W. Baird from $362.00 to $363.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s price target points to a potential upside of 17.74% from the company’s previous close.

A number of other analysts have also weighed in on the company. Truist Financial raised their target price on ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. Mizuho restated a “buy” rating and issued a $346.00 target price on shares of ICON Public in a research note on Thursday, April 4th. Evercore ISI raised their target price on ICON Public from $325.00 to $350.00 and gave the company an “outperform” rating in a research note on Friday, February 23rd. Finally, Barclays raised their target price on ICON Public from $325.00 to $355.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $321.64.

ICON Public Stock Up 2.7 %

Shares of NASDAQ ICLR opened at $308.31 on Friday. The stock has a market cap of $25.44 billion, a PE ratio of 37.51, a PEG ratio of 1.42 and a beta of 1.15. The business has a fifty day moving average of $318.89 and a two-hundred day moving average of $283.09. ICON Public has a 52-week low of $181.92 and a 52-week high of $344.77. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.21 and a current ratio of 1.21.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, February 21st. The medical research company reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.27 by $0.13. The company had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.08 billion. ICON Public had a return on equity of 11.70% and a net margin of 8.30%. As a group, equities research analysts expect that ICON Public will post 14.4 earnings per share for the current fiscal year.

Institutional Trading of ICON Public

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Liontrust Investment Partners LLP increased its position in ICON Public by 108.4% in the third quarter. Liontrust Investment Partners LLP now owns 89,860 shares of the medical research company’s stock worth $22,129,000 after purchasing an additional 46,739 shares during the period. Chartwell Investment Partners LLC grew its position in shares of ICON Public by 16.1% during the 3rd quarter. Chartwell Investment Partners LLC now owns 6,953 shares of the medical research company’s stock worth $1,712,000 after buying an additional 963 shares during the period. Whittier Trust Co. grew its position in shares of ICON Public by 6.2% during the 4th quarter. Whittier Trust Co. now owns 2,702 shares of the medical research company’s stock worth $765,000 after buying an additional 158 shares during the period. Cullen Investment Group LTD. acquired a new position in shares of ICON Public during the 4th quarter worth about $1,620,000. Finally, Prime Capital Investment Advisors LLC acquired a new position in shares of ICON Public during the 4th quarter worth about $416,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.